Tecentriq – Display Banners Conference – 31382
ASCO: A Focus on Lung Cancer
ASCO Lung Cancer Annual 2022.indd
Once-Daily Radiotherapy Preferred by Patients With Limited Stage Small Cell Lung Cancer
High-dose, once-daily thoracic radiotherapy (TRT) and standard twice daily TRT were well tolerated...
Quadruple Therapy Phase II Data for EGFR-mutated NSCLC
Atezolizumab plus bevacizumab plus carboplatin plus paclitaxel (ABCP) is a promising regimen for...
Add-on Tiragolumab Doesn’t Improve on Atezolizumab in Extensive Stage Small Cell Lung Cancer
A Late-breaking session at the American Society of Clinical Oncology (ASCO) 2022 Annual meeting,...
SKYSCRAPER-02: Additional Tiragolumab Does Not Help Patients With Untreated SCLC
Tiragolumab, added to atezolizumab, carboplatin, and etoposide, did not improve the...
ASCO Voices Event
This year ASCO Voices will be held on Saturday, June 4, from 12:00 PM – 1:00 PM CDT, at the Arie Crown Theater in McCormick Place Here are this year’s ASCO Voices: Cancer: Common Humanity, Different Worlds Kevin...
Continuing Education At ASCO 2022
Sessions at the 2022 ASCO Annual Meeting offer Continuing Medical Education (CME) credits and ABIM and ABP Maintenance of Certification (MOC) points for physicians. Nursing and pharmacy CE credits will not be provided this year,...
Why To Attend ASCO 2022
Join more than 40,000 oncology professionals from around the world at the 2022 ASCO Annual Meeting. Stay up to date on new clinical cancer advances in every area of cancer research, gain real-time insights from world-renown...
YAP-1: Immunotherapy Efficacy in ES-SCLC Patients
In extensive-stage small-cell lung cancer (ES-SCLC), IMpower133 improved progression-free survival...
Low-Dose Radiotherapy Plus Atezolizumab & Chemotherapy Benefits ES-SCLC
Researchers conducted the MATCH study to assess the clinical benefits of adding low-dose...
ES-SCLC: Anti-PD-L1 Blockades With Etoposide & Platinum
According to IMpower133 and CASPIAN, anti-PD-L1 blockades combined with etoposide and platinum...
